<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mimmun</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинская иммунология</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Immunology (Russia)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1563-0625</issn><issn pub-type="epub">2313-741X</issn><publisher><publisher-name>SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15789/1563-0625-2011-1-101-104</article-id><article-id custom-type="elpub" pub-id-type="custom">mimmun-432</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КРАТКИЕ СООБЩЕНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>SHORT COMMUNICATIONS</subject></subj-group></article-categories><title-group><article-title>ВЛИЯНИЕ ТЕРАПИИ СИМВАСТАТИНОМ НА ИММУНОЛОГИЧЕСКИЕ МАРКЕРЫ АТЕРОСКЛЕРОЗА У БОЛЬНЫХ РЕВМАТОИДНЫМ АРТРИТОМ</article-title><trans-title-group xml:lang="en"><trans-title>EFFECT OF SIMVASTATIN THERAPY UPON IMMUNOLOGICAL MARKERS OF ATHEROSCLEROSIS IN THE PATIENTS WITH RHEUMATOID ARTHRITIS</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ширинский</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shirinsky</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лаборатория клинической иммунофармакологии</p><p>630099, г. Новосибирск, ул. Ядринцевская 14.</p></bio><email xlink:type="simple">ishirinsky@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ширинский</surname><given-names>В. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Shirinsky</surname><given-names>V. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лаборатория клинической иммунофармакологии</p></bio><email xlink:type="simple">ishirinsky@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Российская академия медицинских наук Научно-исследовательского института клинической иммунологии СО РАМН, г. Новосибирск<country>Россия</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2011</year></pub-date><pub-date pub-type="epub"><day>21</day><month>07</month><year>2014</year></pub-date><volume>13</volume><issue>1</issue><fpage>101</fpage><lpage>104</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ширинский И.В., Ширинский В.С., 2014</copyright-statement><copyright-year>2014</copyright-year><copyright-holder xml:lang="ru">Ширинский И.В., Ширинский В.С.</copyright-holder><copyright-holder xml:lang="en">Shirinsky I.V., Shirinsky V.S.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.mimmun.ru/mimmun/article/view/432">https://www.mimmun.ru/mimmun/article/view/432</self-uri><abstract/><trans-abstract xml:lang="en"/><kwd-group xml:lang="ru"><kwd>ревматоидный артрит</kwd><kwd>атеросклероз</kwd><kwd>маркеры атеросклероза</kwd><kwd>лечение</kwd><kwd>статины</kwd></kwd-group><kwd-group xml:lang="en"><kwd>rheumatoid arthritis</kwd><kwd>atherosclerosis</kwd><kwd>immunological markers</kwd><kwd>treatment</kwd><kwd>statins</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ширинский И.В., Желтова О.И., Ширинский В.С., Козлов В.А. Влияние симвастатина на активность болезни и содержание холестерина субфракций липопротеинов сыворотки крови у больных ревматоидным артритом // Терапевтический архив. – 2008. – № 3. – С. 63-65.</mixed-citation><mixed-citation xml:lang="en">Ширинский И.В., Желтова О.И., Ширинский В.С., Козлов В.А. Влияние симвастатина на активность болезни и содержание холестерина субфракций липопротеинов сыворотки крови у больных ревматоидным артритом // Терапевтический архив. – 2008. – № 3. – С. 63-65.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов Е.Л. Иммунологические маркеры атеросклероза // Терапевтический архив. – 2002. – № 5. – С. 57-60.</mixed-citation><mixed-citation xml:lang="en">Насонов Е.Л. Иммунологические маркеры атеросклероза // Терапевтический архив. – 2002. – № 5. – С. 57-60.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ребров А.П.,Воскобой И.П. Роль воспалительных и инфекционных факторов в развитии атеросклероза // Терапевтический архив. – 2004. – № 1. – С. 78-82.</mixed-citation><mixed-citation xml:lang="en">Ребров А.П.,Воскобой И.П. Роль воспалительных и инфекционных факторов в развитии атеросклероза // Терапевтический архив. – 2004. – № 1. – С. 78-82.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ширинский И.В., Желтова О.И., Соловьева Н.Ю., Ширинский В.С., Козлов В.А. Эффективность и безопасность симвастатина при ревматоидном артрите открытое контролируемое исследование // Медицинская иммунология. – 2007. – № 4-5. – С. 477-482.</mixed-citation><mixed-citation xml:lang="en">Ширинский И.В., Желтова О.И., Соловьева Н.Ю., Ширинский В.С., Козлов В.А. Эффективность и безопасность симвастатина при ревматоидном артрите открытое контролируемое исследование // Медицинская иммунология. – 2007. – № 4-5. – С. 477-482.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Gabriel S.E. Cardiovascular morbidity and mortality in rheumatoid arthritis // Am. J. Med. – 2008. – Vol. 121. – P. 9-14.</mixed-citation><mixed-citation xml:lang="en">Gabriel S.E. Cardiovascular morbidity and mortality in rheumatoid arthritis // Am. J. Med. – 2008. – Vol. 121. – P. 9-14.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Gabriel S.E., Crowson C.S., Kremers H.M., Doran M.F., Turesson C., O’Fallon W.M., Matteson E.L. Survival in rheumatoid arthritis: a populationbased analysis of trends over 40 years // Arthritis Rheum. – 2003. – Vol. 48. – P. 54-58.</mixed-citation><mixed-citation xml:lang="en">Gabriel S.E., Crowson C.S., Kremers H.M., Doran M.F., Turesson C., O’Fallon W.M., Matteson E.L. Survival in rheumatoid arthritis: a populationbased analysis of trends over 40 years // Arthritis Rheum. – 2003. – Vol. 48. – P. 54-58.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Goodson N.J., Symmons D.P., Scott D.G., Bunn D., Lunt M., Silman A.J. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort // Arthritis Rheum. – 2005. – Vol. 52. – P. 2293-2299.</mixed-citation><mixed-citation xml:lang="en">Goodson N.J., Symmons D.P., Scott D.G., Bunn D., Lunt M., Silman A.J. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort // Arthritis Rheum. – 2005. – Vol. 52. – P. 2293-2299.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Harris T.B., Ferrucci L., Tracy R.P., Corti M.C., Wacholder S., Ettinger W.H., Jr., Heimovitz H., Cohen H.J., Wallace R. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly // Am. J. Med. – 1999. – Vol. 106. – P. 506-512.</mixed-citation><mixed-citation xml:lang="en">Harris T.B., Ferrucci L., Tracy R.P., Corti M.C., Wacholder S., Ettinger W.H., Jr., Heimovitz H., Cohen H.J., Wallace R. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly // Am. J. Med. – 1999. – Vol. 106. – P. 506-512.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Hedman A., Larsson P.T., Alam M., Wallen N.H., Nordlander R., Samad B.A. CRP, IL-6 and endothelin1 levels in patients undergoing coronary artery bypass grafting. Do preoperative inflammatory parameters predict early graft occlusion and late cardiovascular events? // Int. J. Cardiol. – 2007. – Vol. 120. – P. 108-114.</mixed-citation><mixed-citation xml:lang="en">Hedman A., Larsson P.T., Alam M., Wallen N.H., Nordlander R., Samad B.A. CRP, IL-6 and endothelin1 levels in patients undergoing coronary artery bypass grafting. Do preoperative inflammatory parameters predict early graft occlusion and late cardiovascular events? // Int. J. Cardiol. – 2007. – Vol. 120. – P. 108-114.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Mazer S.P., Rabbani L.E. Evidence for Creactive protein’s role in (CRP) vascular disease: atherothrombosis, immuno-regulation and CRP // J. Thromb. Thrombolysis. – 2004. – Vol. 17. – P. 95-105.</mixed-citation><mixed-citation xml:lang="en">Mazer S.P., Rabbani L.E. Evidence for Creactive protein’s role in (CRP) vascular disease: atherothrombosis, immuno-regulation and CRP // J. Thromb. Thrombolysis. – 2004. – Vol. 17. – P. 95-105.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Nakou E.S., Liberopoulos E.N., Milionis H.J., Elisaf M.S. The role of C-reactive protein in atherosclerotic cardiovascular disease: an overview // Curr Vasc Pharmacol. – 2008. – Vol. 6. – P. 258-270.</mixed-citation><mixed-citation xml:lang="en">Nakou E.S., Liberopoulos E.N., Milionis H.J., Elisaf M.S. The role of C-reactive protein in atherosclerotic cardiovascular disease: an overview // Curr Vasc Pharmacol. – 2008. – Vol. 6. – P. 258-270.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Retterstol L., Eikvar L., Bohn M., Bakken A., Erikssen J., Berg K. C-reactive protein predicts death in patients with previous premature myocardial infarction – a 10 year follow-up study // Atherosclerosis. – 2002. – Vol. 160. – P. 433-440.</mixed-citation><mixed-citation xml:lang="en">Retterstol L., Eikvar L., Bohn M., Bakken A., Erikssen J., Berg K. C-reactive protein predicts death in patients with previous premature myocardial infarction – a 10 year follow-up study // Atherosclerosis. – 2002. – Vol. 160. – P. 433-440.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Ridker P.M., Rifai N., Stampfer M.J., Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men // Circulation. – 2000. – Vol. 101. – P. 1767-1772.</mixed-citation><mixed-citation xml:lang="en">Ridker P.M., Rifai N., Stampfer M.J., Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men // Circulation. – 2000. – Vol. 101. – P. 1767-1772.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Rye K.A., Barter P.J. Antiinflammatory actions of HDL: a new insight // Arterioscler. Thromb. Vasc. Biol. – 2008. – Vol. 28. – P. 1890-1891.</mixed-citation><mixed-citation xml:lang="en">Rye K.A., Barter P.J. Antiinflammatory actions of HDL: a new insight // Arterioscler. Thromb. Vasc. Biol. – 2008. – Vol. 28. – P. 1890-1891.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Shirinsky I.V., Zheltova O.I., Solovyova N.Y., Kozlov V.A., Shirinsky V.S. Changes in disease activity, cytokine production, and proliferation of peripheral blood mononuclear cells in patients with rheumatoid arthritis after simvastatin treatment // Scand. J. Rheumatol. – 2009. – Vol. 38. – P. 23-27.</mixed-citation><mixed-citation xml:lang="en">Shirinsky I.V., Zheltova O.I., Solovyova N.Y., Kozlov V.A., Shirinsky V.S. Changes in disease activity, cytokine production, and proliferation of peripheral blood mononuclear cells in patients with rheumatoid arthritis after simvastatin treatment // Scand. J. Rheumatol. – 2009. – Vol. 38. – P. 23-27.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Stoll G., Bendszus M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization // Stroke. – 2006. – Vol. 37. – P. 1923-1932.</mixed-citation><mixed-citation xml:lang="en">Stoll G., Bendszus M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization // Stroke. – 2006. – Vol. 37. – P. 1923-1932.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">van Doornum S., McColl G., Wicks I.P. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? // Arthritis Rheum. – 2002. – Vol. 46. – P. 862-873.</mixed-citation><mixed-citation xml:lang="en">van Doornum S., McColl G., Wicks I.P. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? // Arthritis Rheum. – 2002. – Vol. 46. – P. 862-873.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">van Gestel A.M., Prevoo M.L., van′t Hof M.A., van Rijswijk M.H., van de Putte L.B., van Riel P.L. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria // Arthritis Rheum. – 1996. –Vol. 39. – P. 34-40.</mixed-citation><mixed-citation xml:lang="en">van Gestel A.M., Prevoo M.L., van′t Hof M.A., van Rijswijk M.H., van de Putte L.B., van Riel P.L. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria // Arthritis Rheum. – 1996. –Vol. 39. – P. 34-40.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
